E-viri
Recenzirano
Odprti dostop
-
Harley, John B; Pyarajan, Saiju; Partan, Elizabeth S; Epstein, Lauren; Wertheim, Jason A; Diwan, Abhinav; Woods, Christopher W; Davey, Victoria; Blair, Sharlene; Clark, Dennis H; Kaufman, Kenneth M; Khan, Shagufta; Chepelev, Iouri; Devine, Alexander; Cameron, Perry; McCann, Monica F; Ammons, Mary Cloud B; Bolz, Devin D; Battles, Jane K; Curtis, Jeffrey L; Holodniy, Mark; Marconi, Vincent C; Searles, Charles D; Beenhouwer, David O; Brown, Sheldon T; Moorman, Jonathan P; Yao, Zhi Q; Rodriguez-Barradas, Maria C; Mohapatra, Shyam; Molina De Rodriguez, Osmara Y; Padiernos, Emerson B; McIndoo, Eric R; Price, Emily; Burgoyne, Hailey M; Robey, Ian; Schwenke, Dawn C; Shive, Carey L; Przygodzki, Ronald M; Ramoni, Rachel B; Krull, Holly K; Bonomo, Robert A
Open forum infectious diseases, 12/2022, Letnik: 9, Številka: 12Journal Article
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has demonstrated the need to share data and biospecimens broadly to optimize clinical outcomes for US military Veterans. In response, the Veterans Health Administration established VA SHIELD (Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases), a comprehensive biorepository of specimens and clinical data from affected Veterans to advance research and public health surveillance and to improve diagnostic and therapeutic capabilities. VA SHIELD now comprises 12 sites collecting de-identified biospecimens from US Veterans affected by SARS-CoV-2. In addition, 2 biorepository sites, a data processing center, and a coordinating center have been established under the direction of the Veterans Affairs Office of Research and Development. Phase 1 of VA SHIELD comprises 34 157 samples. Of these, 83.8% had positive tests for SARS-CoV-2, with the remainder serving as contemporaneous controls. The samples include nasopharyngeal swabs (57.9%), plasma (27.9%), and sera (12.5%). The associated clinical and demographic information available permits the evaluation of biological data in the context of patient demographics, clinical experience and management, vaccinations, and comorbidities. VA SHIELD is representative of US national diversity with a significant potential to impact national healthcare. VA SHIELD will support future projects designed to better understand SARS-CoV-2 and other emergent healthcare crises. To the extent possible, VA SHIELD will facilitate the discovery of diagnostics and therapeutics intended to diminish COVID-19 morbidity and mortality and to reduce the impact of new emerging threats to the health of US Veterans and populations worldwide.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.